SG10201909382UA - Glyt1 inhibitors for use in the treatment of hematological disorders - Google Patents
Glyt1 inhibitors for use in the treatment of hematological disordersInfo
- Publication number
- SG10201909382UA SG10201909382UA SG10201909382UA SG10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- hematological disorders
- glyt1 inhibitors
- glyt1
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000014951 hematologic disease Diseases 0.000 title abstract 2
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 abstract 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 abstract 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 abstract 1
- 206010065973 Iron Overload Diseases 0.000 abstract 1
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 abstract 1
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 abstract 1
- 208000002903 Thalassemia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166497 | 2014-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201909382UA true SG10201909382UA (en) | 2019-11-28 |
Family
ID=50677958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608397UA SG11201608397UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
| SG10201909382U SG10201909382UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608397UA SG11201608397UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9877963B2 (tr) |
| EP (1) | EP3137073B1 (tr) |
| JP (1) | JP6283766B2 (tr) |
| KR (1) | KR101869185B1 (tr) |
| CN (1) | CN106163520B (tr) |
| AR (1) | AR100209A1 (tr) |
| CY (1) | CY1120508T1 (tr) |
| ES (1) | ES2683184T3 (tr) |
| HR (1) | HRP20181205T1 (tr) |
| MA (1) | MA39927B1 (tr) |
| MY (1) | MY189930A (tr) |
| PH (1) | PH12016501784A1 (tr) |
| PT (1) | PT3137073T (tr) |
| RS (1) | RS57535B1 (tr) |
| SG (2) | SG11201608397UA (tr) |
| SI (1) | SI3137073T1 (tr) |
| TR (1) | TR201809598T4 (tr) |
| WO (1) | WO2015165842A1 (tr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199156A1 (de) * | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika |
| CU20200106A7 (es) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| AU2021205510A1 (en) | 2020-01-09 | 2022-07-21 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| EP4304597A1 (en) * | 2021-03-12 | 2024-01-17 | Disc Medicine, Inc. | Compositions and methods for treating anemia associated with a ribosomal disorder |
| AU2022273051A1 (en) * | 2021-05-14 | 2023-12-07 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| CA3220741A1 (en) * | 2021-05-27 | 2022-12-01 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
| WO2023235326A1 (en) * | 2022-05-31 | 2023-12-07 | Disc Medicine, Inc. | Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00116B (me) * | 2003-08-11 | 2010-10-10 | Hoffmann La Roche | Piperazin sa ili supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1 |
| DE602006010665D1 (en) * | 2005-02-07 | 2010-01-07 | Hoffmann La Roche | Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1 |
-
2015
- 2015-04-27 JP JP2017505724A patent/JP6283766B2/ja active Active
- 2015-04-27 SG SG11201608397UA patent/SG11201608397UA/en unknown
- 2015-04-27 EP EP15717916.9A patent/EP3137073B1/en active Active
- 2015-04-27 KR KR1020167030222A patent/KR101869185B1/ko active IP Right Grant
- 2015-04-27 PT PT157179169T patent/PT3137073T/pt unknown
- 2015-04-27 SG SG10201909382U patent/SG10201909382UA/en unknown
- 2015-04-27 CN CN201580016721.4A patent/CN106163520B/zh active Active
- 2015-04-27 TR TR2018/09598T patent/TR201809598T4/tr unknown
- 2015-04-27 WO PCT/EP2015/059037 patent/WO2015165842A1/en active Application Filing
- 2015-04-27 RS RS20180897A patent/RS57535B1/sr unknown
- 2015-04-27 MA MA39927A patent/MA39927B1/fr unknown
- 2015-04-27 ES ES15717916.9T patent/ES2683184T3/es active Active
- 2015-04-27 MY MYPI2016001545A patent/MY189930A/en unknown
- 2015-04-27 SI SI201530334T patent/SI3137073T1/sl unknown
- 2015-04-28 AR ARP150101268A patent/AR100209A1/es not_active Application Discontinuation
-
2016
- 2016-09-13 PH PH12016501784A patent/PH12016501784A1/en unknown
- 2016-10-26 US US15/334,722 patent/US9877963B2/en active Active
-
2018
- 2018-07-25 HR HRP20181205TT patent/HRP20181205T1/hr unknown
- 2018-08-06 CY CY20181100809T patent/CY1120508T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160130517A (ko) | 2016-11-11 |
| US20170042888A1 (en) | 2017-02-16 |
| CN106163520A (zh) | 2016-11-23 |
| MA39927B1 (fr) | 2018-09-28 |
| HRP20181205T1 (hr) | 2018-09-21 |
| PT3137073T (pt) | 2018-07-27 |
| EP3137073A1 (en) | 2017-03-08 |
| ES2683184T3 (es) | 2018-09-25 |
| MY189930A (en) | 2022-03-22 |
| JP2017511385A (ja) | 2017-04-20 |
| WO2015165842A1 (en) | 2015-11-05 |
| CN106163520B (zh) | 2019-12-13 |
| US9877963B2 (en) | 2018-01-30 |
| MA39927A (fr) | 2017-03-08 |
| KR101869185B1 (ko) | 2018-06-19 |
| EP3137073B1 (en) | 2018-06-06 |
| RS57535B1 (sr) | 2018-10-31 |
| PH12016501784B1 (en) | 2016-11-07 |
| SG11201608397UA (en) | 2016-11-29 |
| PH12016501784A1 (en) | 2016-11-07 |
| AR100209A1 (es) | 2016-09-21 |
| CY1120508T1 (el) | 2019-07-10 |
| SI3137073T1 (sl) | 2018-09-28 |
| TR201809598T4 (tr) | 2018-07-23 |
| JP6283766B2 (ja) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018236800B2 (en) | DNA-PK inhibitors | |
| SG10201909382UA (en) | Glyt1 inhibitors for use in the treatment of hematological disorders | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| WO2016004068A8 (en) | Hydrogel compositions comprising encapsulated cells and methods of use thereof | |
| IN2015DN01156A (tr) | ||
| SG10201909545XA (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| WO2014062720A3 (en) | Methods of treating cancer | |
| NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| IN2014DN10386A (tr) | ||
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| MY189912A (en) | Substituted xanthines and methods of use thereof | |
| EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
| NZ630615A (en) | Thiadiazolidinediones as gsk-3 inhibitors | |
| MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
| EA201692289A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| WO2013169631A3 (en) | Wnt protein signalling inhibitors | |
| WO2014186450A3 (en) | Highly potent inhibitors of porcupine | |
| MX363385B (es) | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. | |
| EP2964750A4 (en) | METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES | |
| EP2994156A4 (en) | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity |